Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 8, 2017
Distillery Therapeutics

Autoimmune disease; inflammation

BioCentury | May 12, 2014
Strategy

Build up to break up

Why Pfizer needs AstraZeneca to make a break-up plan work
BioCentury | Nov 5, 2012
Clinical News

Brodalumab: Phase III started

BioCentury | Apr 2, 2012
Clinical News

Brodalumab: Phase II data

BioCentury | Mar 29, 2012
Clinical News

Amgen's anti-IL-17R mAb meets psoriasis endpoint

Items per page:
1 - 6 of 6